ELTX News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: Getty Images (GETY) 52.17% +2.55, Angion Biomedica Corp (ELTX) 97.66% +2.04, Banco Bradesco (BBD) 2.69% +1.61, Alpha Tau Medical Ltd (DRTS) 8.90% +1.59, T-REX 2X LONG HOOD DAILY TARGET (ROBN) 6.96% +0.74, Tidal Trust II (IRE) 21.76% +0.68, Ambarella (AMBA) 3.64% +0.58, United States Oil Fund (USO) 6.27% +0.55, Nebius Group NV (NBIS) 1.87% +0.53, and Vivopower Plc (VIVO) 18.57% +0.49.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Starfighters Space, Inc. (FJET) 116.23% +6.71, SpendSmart Networks Inc (SSPC) 58.19% +6.31, Leverage Shares 2X Long SPCX Daily ETF (SPCH) 50.00% +5.10, Critical Metals Corp (CRML) 67.53% +4.11, Advanced Semiconductor (ASX) 14.23% +3.43, Ambarella (AMBA) 3.65% +3.37, Tilray (TLRY) 9.36% +3.00, Angion Biomedica Corp (ELTX) 113.87% +1.97, Microvision (MVIS) 63.24% +1.41, and Defiance Daily Target 2x Long OKLO ETF (OKLL) 14.35% +1.33.

Elicio Therapeutics announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4.38M shares of its common stock pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $15M, before deducting placement agents' fees and other offering expenses. The closing of the offering is expected to occur on or about July 6, subject to the satisfaction of customary closing conditions. Elicio intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and Elicio's pipeline and platform, as well as for working capital and general corporate purposes. Titan Partners is acting as lead placement agent for the Offering. B. Riley Securities, Inc. is acting as co-placement agent for the offering.